Boston Scientific adds dystonia indication to CE Mark for Vercise DBS device
Boston Scientific's Vercise deep-brain stimulation wins CE Mark approval in the European Union for treating dystonia.
Boston Scientific said it won CE Mark approval in the European Union for its Vercise deep-brain stimulation device for treating the movement disorder called dystonia.
The Vercise device is already approved in the EU for treating Parkinson's disease. The new approval clears Natick, Mass.-based Boston Scientific' Vercise for the treatment of intractable primary and secondary dystonia, according to a press release.
"The Vercise DBS System's advanced technology has already demonstrated significant improvements in motor scores for patients with Parkinson's disease as evidenced by the interim results from our Vantage multicenter clinical trial," Maulik Nanavaty, president of Boston Scientific's neuromodulation division, said in prepared remarks. "With this approval we look forward to extending the use of this technology to improve the quality of life of patients with dystonia."